Johnson CC, Burkman RT, Gold MA, Brown RT, Harel Z, Bruner A, et al. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density. Contraception 2008;77:239–48. ACOG is a nonprofit organization of women's health care physicians advocating highest standards of practice, continuing member education and public awareness of women's health care issues. Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 2012; 85:458. Contraception 2012; 85:458. Beasley A, White KO, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. The Society for Adolescent Medicine’s Depo-Provera guidelines state that the duration of use does not need to be restricted to two years; the World Health Organization’s (WHO) and American College of Obstetricians and Gynecologists’ (ACOG) guidelines do not place any restrictions on the length of Depo use in women aged 18-45. 33,34 The Practice Committee of the American Society for. February 2005 page 4 Depo-Provera’s black box: 4Women who use Depo-Provera Contraceptive Injection may lose signifi cant bone mineral density. Patient Information About depo-subQ provera 104™ medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD Depo-Provera 150 mg/1 ml is administered by intramuscular injection and Depo-subQ 104 mg/0.65 ml is administered by subcutaneous injection. Although the dose and mode of delivery are different, both Depo-Provera IM and Depo-subQ are similar in efficacy and side effect profile. This collection features the best content from AFP, as identified by the AFP editors, on family planning and contraception and related issues, including emergency contraception, hormonal and non. Contraceptive Injection. The effect of hepatic and/or renal disease on the pharmacokinetics of DEPO-PROVERA Contraceptive Injection is unknown. Data are conflicting regarding the effects of Depo-Provera on depression.62, 63 ACOG has concluded that Depo-Provera does not worsen depressive symptoms.6 Depo-Provera reduces serum estradiol.